Government-Owned Inventions; Availability for Licensing, 30952-30954 [E8-11919]
Download as PDF
<![CDATA[
30952
Federal Register / Vol. 73, No. 104 / Thursday, May 29, 2008 / Notices
the viral subtypes currently transmitted
within the screened population and
hence most likely to ‘‘break-through’’
routine screening measures (i.e., periseroconversion window period
donations). Molecular surveillance of
incident HIV infections in blood donors
not only characterizes genotypes of
recently infected donors for purposes of
blood safety, but also enables
documentation of the rates of primary
transmission of anti-viral drug resistant
strains in the community, serving a
public health role in identifying new
HIV infections for anti-retroviral
treatment. Both a prospective
surveillance and a case-control design
are proposed to enroll all eligible HIV
seropositives detected at three blood
˜
centers in Brazil (Sao Paulo, Belo
´
Horizante, and Recıfe) plus a satellite
center in Rio de Janeiro. A comparison
of epidemiological risk profiles will be
made between the seropositive donors
and a group of randomly selected
seronegative donors.
There are three study aims.
Laboratory studies (LS–EIA testing and
sequencing of pol region) on linked
specimens from all enrolled HIV cases,
will allow for estimation of HIV
prevalence and incidence relative to
genotype and putative route of
infection. Data derived from molecular
genotyping, including drug resistant
genotypes, will be provided, along with
counseling, to all enrolled HIV positive
donors to facilitate their clinical care via
referral to the Brazilian national HIV
treatment system. Our findings will be
compared to trends in prevalence,
incidence and molecular variants from
studies of the general population and
high risk populations in Brazil, thus
allowing for broad monitoring of the
HIV epidemic in Brazil and assessment
of the impact of donor selection criteria
on these parameters. Finally, HIV cases
and a group of controls, through
responses to a questionnaire, will
provide data on HIV risk behaviors
among prospective blood donors. This
HIV risk behavior data will be used as
covariates in the molecular surveillance
analyses described above, as well as aid
in assessing whether modifications may
be needed to Brazil’s routine blood
center operational donor screening
questionnaire.
The study participants will return to
their local blood center for the
administration of an informed consent
form, explaining the confidential nature
of the research study as well as the risks
and benefits to their participation. Once
enrolled, they will be asked to complete
the self-administered risk factor
questionnaire. In addition, a small blood
sample will be collected from each HIV
seropositive participant to be used for
the genotyping and drug resistance
testing. The results of the drug
resistance testing will be communicated
back to the seropositive participants
during an in-person counseling session
at the blood center. Defining prevalence
and incidence in blood donors and
residual risk of HIV transmission by
Estimated
number of
responses per
respondent
Estimated
number of
respondents
jlentini on PROD1PC65 with NOTICES
2,000 ................................................................................................................................
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies should
address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and the assumptions used;
(3) Ways to enhance the quality, utility,
and clarity of the information collected;
and (4) Ways to minimize the burden of
the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
VerDate Aug<31>2005
17:45 May 28, 2008
Jkt 214001
transfusions may lead to new
regulations and blood safety initiatives
in Brazil. The data can be used to
project the yield, safety impact and cost
effectiveness of implementing enhanced
testing strategies such as combination
antigen-antibody assays and/or NAT.
Determination of HIV risk factors in
donors (first time versus repeat donor
status; volunteer versus replacement
status; demographics and risk
behaviors) will support policy
discussions over strategies to recruit the
safest possible donors in Brazil. The
findings from this project will also
complement similar monitoring of HIV
prevalence, incidence, transfusion risk
and molecular variants in the U.S. and
other funded international REDS-II sites,
thus allowing direct comparisons of
these parameters on a global level.
Frequency of Response: Once.
Affected Public: Individuals. Type of
Respondents: Adult Blood Donors. The
annual reporting burden is as follows:
Estimated Number of Respondents:
2,000; Estimated Number of Responses
per Respondent: 1; Average Burden of
Hours per Response: 0.40 (including
administration of the informed consent
form and questionnaire completion
instructions); and Estimated Total
Annual Burden Hours Requested: 800.
The annualized cost to respondents is
estimated at: $5,200 (based on $6.50 per
hour). There are no Capital Costs to
report. There are no Operating or
Maintenance Costs to report.
collection techniques or other forms of
information technology.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Dr. George Nemo,
Project Officer, NHLBI, Two Rockledge
Center, Room 9144, 6701 Rockledge
Drive, MSC 7950, Bethesda, MD 20892–
7950, or call 301–435–0065, orE-mail
your request to nemog@nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT:
PO 00000
Average burden
hours per
response
1
Estimated
total annual
burden hours
requested
0.40
800
Dated: May 20, 2008.
George Nemo,
Project Officer, NHLBI, National Institutes of
Health.
[FR Doc. E8–11921 Filed 5–28–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Frm 00073
Fmt 4703
Sfmt 4703
E:\FR\FM\29MYN1.SGM
29MYN1
Federal Register / Vol. 73, No. 104 / Thursday, May 29, 2008 / Notices
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
jlentini on PROD1PC65 with NOTICES
Telomerase Suppressor Compositions
and Methods for Diagnosis and
Treatment of Cancer
Description of Technology: Lung
cancer is responsible for one-third of all
cancer related deaths. Although tobacco
smoking is a major cause of lung cancer,
epidemiological studies have provided
evidence for the involvement of genetic
factors in the disease onset. For now
there are no reliable markers for the
early lung cancer diagnostics and no
effective treatment except resection of
the tumor on early stages. As a result,
it is difficult to diagnose lung cancer
without invasive methods and before
significant progression of the disease
has occurred.
NIH inventors have recently
discovered that a gene called CCDC36
(LELA1) is frequently inactivated in
patients with non-small cell lung cancer
(NSCLC). In many instances of lung
cancer, particularly early onset NSCLC,
one copy of CCDC36 will be lost due to
the chromosomal deletion while the
other will be inactivated by promoter
methylation. This results in reduction or
loss of CCDC36 gene expression. In
addition, several single nucleotide
polymorphisms (SNPs) found in the
gene appeared to be associated with the
early onset NSCLC. CCDC36 gene
replacement could be utilized as a
potential therapeutic strategy.
Applications
Detection of SNPs associated with
early onset NSCLC can be potentially
used to diagnose predisposition.
Detection of chromosomal loss of
CCDC36 and/or its methylation status in
lung cancer can be used to diagnose
NSCLC.
Treatment of NSCLC using CCDC36based therapeutics.
VerDate Aug<31>2005
17:45 May 28, 2008
Jkt 214001
Advantages
Early detection of NSCLC has the
potential to improve prognosis of lung
cancer patient.
Non-invasive nature of the test is
beneficial to patient comfort.
Benefits
There is no current genetic test for
early onset NSCLC, providing an
excellent market opportunity.
Developing a diagnostic test for lung
cancer will have significant social
benefits, allowing the early detection
and treatment of lung cancer patients.
Inventors: Tatiana Dracheva et al.
(NCI).
Patent Status: PCT Application No.
PCT/US2008/059800 filed 09 Apr 2008
(HHS Reference No. E–265–2007/0–
PCT–01).
Licensing Status: Available for
licensing.
Licensing Contact: David A.
Lambertson, Ph.D.; 301–435–4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute, Center for
Cancer Research, Laboratory of Human
Carcinogenesis is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize ‘‘Unique Genetic
Changes in CCDC36 Gene That Are
Associated with Early Onset Lung
Cancer.’’ Please contact John D. Hewes,
Ph.D., at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
Muramyl Dipeptide as a Therapeutic
Agent for Inflammation
Description of Technology: The
nucleotide-binding oligomerization
domain 2 (NOD2) protein plays a key
role in innate immunity as a sensor of
muramyl dipeptide (MDP), a breakdown
product of bacterial peptidoglycan.
Bacterial peptidoglycan promotes the
innate immune response through the
activation of Toll-like receptor 2 (TLR2),
which ultimately provokes
inflammation. Activation of NOD2 by
MDP negatively regulates the activity of
TLR2, and thus reduces inflammation.
The inventors have demonstrated that
administration of MDP prevents the
development of experimental colitis in
mice. They have also determined that
MDP reduces pro-inflammatory
cytokine production from multiple Tolllike receptors, and that this reduction
arises from the induction of IFN
regulatory factor 4 (IRF4). The
technology includes methods of treating
or preventing inflammation associated
with an autoimmune disorder,
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
30953
particularly inflammatory bowel
disease, via administration of muramyl
peptide; also included are methods of
reducing symptoms characteristic of
inflammation via administration of
muramyl peptide.
Applications: This technology has
potential as an anti-inflammatory
therapy for autoimmune or other
inflammation-associated diseases,
particularly inflammatory bowel
diseases such as Crohn’s disease and
ulcerative colitis.
Market: Approximately 1.8 million
people suffer from inflammatory bowel
disease in the major pharmaceutical
markets. In the United States alone,
there are approximately 300,000 to
500,000 people with inflammatory
bowel disease, as estimated by the
National Institute of Diabetes and
Digestive and Kidney Diseases, NIH.
Development Status: In vivo data are
available in an experimental colitis
mouse model, and in vitro data
supporting mechanism of action also are
available.
Inventors: Warren Strober et al.
(NIAID).
Relevant Publication: T. Watanabe et
al. Muramyl dipeptide activation of
nucleotide-binding oligomerization
domain 2 protects mice from
experimental colitis. J Clin Invest. 2008
Feb;118(2):545–559.
Patent Status: PCT Application No.
PCT/US2007/086117 filed 30 Nov 2007
(HHS Reference No. E–110–2006/0–
PCT–02).
Licensing Status: This technology is
available for exclusive or non-exclusive
licensing.
Licensing Contact: Tara Kirby, Ph.D.;
301–435–4426; tarak@mail.nih.gov.
Collaborative Research Opportunity:
The NIAID Laboratory of Host Defenses,
Mucosal Immunity Section, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize this technology. Please
contact either Rosemary Walsh or
Charles Rainwater at 301–496–2644 for
more information.
Treatment and Diagnosis of Cancer,
Diabetes and Other Disorders Using
Adrenomedullin Peptides and
Antibodies
Description of Technology:
Adrenomedullin (AM), a 52-amino acid
regulatory peptide, is expressed in a
wide range of tissues, and has a variety
of biological roles. AM was initially
identified as a vasodilator, and the
effects of AM and its fragments in the
cardiovascular system have been widely
studied. AM also has important effects
on renal function, cell growth, glucose
E:\FR\FM\29MYN1.SGM
29MYN1
30954
Federal Register / Vol. 73, No. 104 / Thursday, May 29, 2008 / Notices
metabolism, and regulation of hormone
secretion, and has antimicrobial
activity.
This technology claims AM peptides
and antibodies, which would be useful
in the development of a therapeutic or
for diagnostics use. Also claimed are
methods of inhibiting tumor cell growth
using AM peptides, in particular in a
patient suffering from a lung tumor.
Claims are also directed to methods of
treating a subject with AM-associated
conditions, including diabetes,
pregnancy, neurological disease,
inflammation, or bone development.
Finally, methods are claimed for
diagnosing or monitoring a disease
where AM levels are altered.
Also available is a murine monoclonal
antibody, MoAb-G6, which was raised
against an AM peptide. This antibody
neutralizes AM bioactivity, and reacts
with the processed form of AM, but not
the preprohormone. This antibody
would be useful not only for research
use, but also as part of a diagnostic
assay for measurement or detection of
AM.
Applications
Peptide- or antibody-based
therapeutics for cancer, diabetes,
inflammation or other AM-associated
disease.
Diagnostic tools for the detection of
AM-positive tumors or other AMassociated conditions.
Research use of AM peptides and
antibodies.
Development Status: This technology
is currently in the pre-clinical stage of
development.
Inventors: Frank Cuttitta et al. (NCI).
Related Publications
´
1. A Martınez et al. Regulation of
insulin secretion and blood glucose
metabolism by adrenomedullin.
Endocrinology. 1996 Jun;137(6):2626–
2632.
2. E Zudaire et al. The central role of
adrenomedullin in host defense. J
Leukoc Biol. 2006 Aug;80(2):237–244.
3. E Zudaire et al. Adrenomedullin is
a cross-talk molecule that regulates
tumor and mast cell function during
human carcinogenesis. Am J Pathol.
2006 Jan;168(1):280–291.
jlentini on PROD1PC65 with NOTICES
Patent Status:
U.S. Patent Serial No. 6,320,022
issued 20 Nov 2001 (HHS Reference No.
E–206–1995/3–US–04).
U.S. Patent Serial No. 7,101,548
issued 05 Sept 2006 (HHS Reference No.
E–206–1995/3–US–10).
U.S. Patent Application No. 11/
517,599 filed 05 Sept 2006 (HHS
Reference No. E–206–1995/3–US–11).
VerDate Aug<31>2005
17:45 May 28, 2008
Jkt 214001
Foreign counterparts in Australia,
Canada, France, Germany, Great Britain,
and Japan.
Related Technologies
HHS Reference No. E–256–1999/0—
Determination of AdrenomedullinBinding Proteins.
HHS Reference No. E–294–2002/0—A
New Target for Angiogenesis and AntiAngiogenesis Therapy.
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Tara Kirby, Ph.D.;
301–435–4426; tarak@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute
Angiogenesis Core Facility is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize Use of Adrenomedullin
Peptides and Antibodies in the
Treatment and Diagnosis of Cancer,
Diabetes and other Disorders. Please
contact John D. Hewes, Ph.D. at 301–
435–3121 or hewesj@mail.nih.gov for
more information.
Dated: May 21, 2008.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–11919 Filed 5–28–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel, June
26, 2008, 1 p.m. to June 26, 2008, 3
p.m., National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
which was published in the Federal
Register on May 16, 2008, 73 FR 28489–
28490.
The meeting will be held June 24,
2008, 2 p.m. to 3 p.m. The meeting
location remains the same. The meeting
is closed to the public.
Dated: May 20, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–11785 Filed 5–28–08; 8:45 am]
BILLING CODE 4140–01–M
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel, June
23, 2008, 8 a.m. to June 24, 2008, 5 p.m.,
Sir Francis Drake Hotel, 450 Powell
Street, San Francisco, CA 94102 which
was published in the Federal Register
on May 16, 2008, 73 FR 28489–28490.
The meeting will be held one day
only June 23, 2008, from 8 a.m. to 7 p.m.
The meeting location remains the same.
The meeting is closed to the public.
Dated: May 20, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–11787 Filed 5–28–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel, June
17, 2008, 1 p.m. to June 17, 2008, 3
p.m., National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
which was published in the Federal
Register on May 15, 2008, 73 FR 28121–
28122.
The meeting will be held June 20,
2008, 11 a.m. to 2 p.m. The meeting
location remains the same. The meeting
is closed to the public.
Dated: May 20, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–11788 Filed 5–28–08; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review;
Cancellation of Meeting
Notice is hereby given of the
cancellation of the Neurotechnology
Study Section, June 3, 2008, 8 a.m. to
June 4, 2008, 5 p.m., Grand Hyatt, 345
Stockton Street, San Francisco, CA
E:\FR\FM\29MYN1.SGM
29MYN1
]]>Agencies
[Federal Register Volume 73, Number 104 (Thursday, May 29, 2008)]
[Notices]
[Pages 30952-30954]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-11919]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
[[Page 30953]]
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Telomerase Suppressor Compositions and Methods for Diagnosis and
Treatment of Cancer
Description of Technology: Lung cancer is responsible for one-third
of all cancer related deaths. Although tobacco smoking is a major cause
of lung cancer, epidemiological studies have provided evidence for the
involvement of genetic factors in the disease onset. For now there are
no reliable markers for the early lung cancer diagnostics and no
effective treatment except resection of the tumor on early stages. As a
result, it is difficult to diagnose lung cancer without invasive
methods and before significant progression of the disease has occurred.
NIH inventors have recently discovered that a gene called CCDC36
(LELA1) is frequently inactivated in patients with non-small cell lung
cancer (NSCLC). In many instances of lung cancer, particularly early
onset NSCLC, one copy of CCDC36 will be lost due to the chromosomal
deletion while the other will be inactivated by promoter methylation.
This results in reduction or loss of CCDC36 gene expression. In
addition, several single nucleotide polymorphisms (SNPs) found in the
gene appeared to be associated with the early onset NSCLC. CCDC36 gene
replacement could be utilized as a potential therapeutic strategy.
Applications
Detection of SNPs associated with early onset NSCLC can be
potentially used to diagnose predisposition.
Detection of chromosomal loss of CCDC36 and/or its methylation
status in lung cancer can be used to diagnose NSCLC.
Treatment of NSCLC using CCDC36-based therapeutics.
Advantages
Early detection of NSCLC has the potential to improve prognosis of
lung cancer patient.
Non-invasive nature of the test is beneficial to patient comfort.
Benefits
There is no current genetic test for early onset NSCLC, providing
an excellent market opportunity.
Developing a diagnostic test for lung cancer will have significant
social benefits, allowing the early detection and treatment of lung
cancer patients.
Inventors: Tatiana Dracheva et al. (NCI).
Patent Status: PCT Application No. PCT/US2008/059800 filed 09 Apr
2008 (HHS Reference No. E-265-2007/0-PCT-01).
Licensing Status: Available for licensing.
Licensing Contact: David A. Lambertson, Ph.D.; 301-435-4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute,
Center for Cancer Research, Laboratory of Human Carcinogenesis is
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
``Unique Genetic Changes in CCDC36 Gene That Are Associated with Early
Onset Lung Cancer.'' Please contact John D. Hewes, Ph.D., at 301-435-
3121 or hewesj@mail.nih.gov for more information.
Muramyl Dipeptide as a Therapeutic Agent for Inflammation
Description of Technology: The nucleotide-binding oligomerization
domain 2 (NOD2) protein plays a key role in innate immunity as a sensor
of muramyl dipeptide (MDP), a breakdown product of bacterial
peptidoglycan. Bacterial peptidoglycan promotes the innate immune
response through the activation of Toll-like receptor 2 (TLR2), which
ultimately provokes inflammation. Activation of NOD2 by MDP negatively
regulates the activity of TLR2, and thus reduces inflammation.
The inventors have demonstrated that administration of MDP prevents
the development of experimental colitis in mice. They have also
determined that MDP reduces pro-inflammatory cytokine production from
multiple Toll-like receptors, and that this reduction arises from the
induction of IFN regulatory factor 4 (IRF4). The technology includes
methods of treating or preventing inflammation associated with an
autoimmune disorder, particularly inflammatory bowel disease, via
administration of muramyl peptide; also included are methods of
reducing symptoms characteristic of inflammation via administration of
muramyl peptide.
Applications: This technology has potential as an anti-inflammatory
therapy for autoimmune or other inflammation-associated diseases,
particularly inflammatory bowel diseases such as Crohn's disease and
ulcerative colitis.
Market: Approximately 1.8 million people suffer from inflammatory
bowel disease in the major pharmaceutical markets. In the United States
alone, there are approximately 300,000 to 500,000 people with
inflammatory bowel disease, as estimated by the National Institute of
Diabetes and Digestive and Kidney Diseases, NIH.
Development Status: In vivo data are available in an experimental
colitis mouse model, and in vitro data supporting mechanism of action
also are available.
Inventors: Warren Strober et al. (NIAID).
Relevant Publication: T. Watanabe et al. Muramyl dipeptide
activation of nucleotide-binding oligomerization domain 2 protects mice
from experimental colitis. J Clin Invest. 2008 Feb;118(2):545-559.
Patent Status: PCT Application No. PCT/US2007/086117 filed 30 Nov
2007 (HHS Reference No. E-110-2006/0-PCT-02).
Licensing Status: This technology is available for exclusive or
non-exclusive licensing.
Licensing Contact: Tara Kirby, Ph.D.; 301-435-4426;
tarak@mail.nih.gov.
Collaborative Research Opportunity: The NIAID Laboratory of Host
Defenses, Mucosal Immunity Section, is seeking statements of capability
or interest from parties interested in collaborative research to
further develop, evaluate, or commercialize this technology. Please
contact either Rosemary Walsh or Charles Rainwater at 301-496-2644 for
more information.
Treatment and Diagnosis of Cancer, Diabetes and Other Disorders Using
Adrenomedullin Peptides and Antibodies
Description of Technology: Adrenomedullin (AM), a 52-amino acid
regulatory peptide, is expressed in a wide range of tissues, and has a
variety of biological roles. AM was initially identified as a
vasodilator, and the effects of AM and its fragments in the
cardiovascular system have been widely studied. AM also has important
effects on renal function, cell growth, glucose
[[Page 30954]]
metabolism, and regulation of hormone secretion, and has antimicrobial
activity.
This technology claims AM peptides and antibodies, which would be
useful in the development of a therapeutic or for diagnostics use. Also
claimed are methods of inhibiting tumor cell growth using AM peptides,
in particular in a patient suffering from a lung tumor. Claims are also
directed to methods of treating a subject with AM-associated
conditions, including diabetes, pregnancy, neurological disease,
inflammation, or bone development. Finally, methods are claimed for
diagnosing or monitoring a disease where AM levels are altered.
Also available is a murine monoclonal antibody, MoAb-G6, which was
raised against an AM peptide. This antibody neutralizes AM bioactivity,
and reacts with the processed form of AM, but not the preprohormone.
This antibody would be useful not only for research use, but also as
part of a diagnostic assay for measurement or detection of AM.
Applications
Peptide- or antibody-based therapeutics for cancer, diabetes,
inflammation or other AM-associated disease.
Diagnostic tools for the detection of AM-positive tumors or other
AM-associated conditions.
Research use of AM peptides and antibodies.
Development Status: This technology is currently in the pre-
clinical stage of development.
Inventors: Frank Cuttitta et al. (NCI).
Related Publications
1. A Martinez et al. Regulation of insulin secretion and blood
glucose metabolism by adrenomedullin. Endocrinology. 1996
Jun;137(6):2626-2632.
2. E Zudaire et al. The central role of adrenomedullin in host
defense. J Leukoc Biol. 2006 Aug;80(2):237-244.
3. E Zudaire et al. Adrenomedullin is a cross-talk molecule that
regulates tumor and mast cell function during human carcinogenesis. Am
J Pathol. 2006 Jan;168(1):280-291.
Patent Status:
U.S. Patent Serial No. 6,320,022 issued 20 Nov 2001 (HHS Reference
No. E-206-1995/3-US-04).
U.S. Patent Serial No. 7,101,548 issued 05 Sept 2006 (HHS Reference
No. E-206-1995/3-US-10).
U.S. Patent Application No. 11/517,599 filed 05 Sept 2006 (HHS
Reference No. E-206-1995/3-US-11).
Foreign counterparts in Australia, Canada, France, Germany, Great
Britain, and Japan.
Related Technologies
HHS Reference No. E-256-1999/0--Determination of Adrenomedullin-
Binding Proteins.
HHS Reference No. E-294-2002/0--A New Target for Angiogenesis and
Anti-Angiogenesis Therapy.
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Tara Kirby, Ph.D.; 301-435-4426;
tarak@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
Angiogenesis Core Facility is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize Use of Adrenomedullin Peptides and
Antibodies in the Treatment and Diagnosis of Cancer, Diabetes and other
Disorders. Please contact John D. Hewes, Ph.D. at 301-435-3121 or
hewesj@mail.nih.gov for more information.
Dated: May 21, 2008.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E8-11919 Filed 5-28-08; 8:45 am]
BILLING CODE 4140-01-P
